Risk for Transfusion-Transmitted Infectious Diseases in Central and South America

Schmuñis, Gabriel A.; Zicker, Fábio; Pinheiro, F. P.; Brandling-Bennett, David

doi:10.3201/eid0401.980102

Cited by 84 publications

(99 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The rate of T. cruzi seropositivity prevalence in our cohort of heart disease patients is relatively high in comparison to that of some other population groups, such as blood donors and asymptomatic inhabitants in highly infested vector areas [3,8,9]. This fact should also call attention to the possibility of a higher T. cruzi infection rate in the Salvadoran population in the last decades than the rates published previously [3,8,9].…”

Section: Discussionmentioning

confidence: 48%

“…This fact should also call attention to the possibility of a higher T. cruzi infection rate in the Salvadoran population in the last decades than the rates published previously [3,8,9].…”

Section: Discussionmentioning

confidence: 84%

“…Moreover, the acute phase of the disease was similarly observed in children and young adults, both Triatoma dimidiate and Rhodniusprolixus vectors were found in the country, and electrocardiographic (ECG) and thoracic radiological (X-ray) changes were less common and milder than those reported in South American countries [7]. In 1998, T. cruzi seroprevalence in El Salvador was estimated to be 14.7 per 100,000 among blood donors [8], then 3.37% among the Salvadoran population in 2005 [4]. Furthermore, the national serological screenings of T. cruzi were first conducted in the late 1990s, reporting an average index of 0.36%, 0.28%, and 2.1% among children younger than 7 years old, 7-to 14-year-old children, and individuals older than 14 years old, respectively [9].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

ELISA seroprevalence of Trypanosoma cruzi in a cohort of heart disease patients

Rodriguez

Hernandez

Garcia

et al. 2013

J Infect Dev Ctries

View full text Add to dashboard Cite

Introduction: Chagas disease is the most important parasitic disease in El Salvador and Latin America. The disease has two phases: acute and chronic, with an intermediate unspecified phase. The chronic phase develops in 30% of infected persons and its most common manifestation is cardiac disease. This study aimed to obtain reference data for the prevalence of T. cruzi seropositivity in a cohort of cardiac patients. Methodology: A cross-sectional study involving consecutive heart disease patients consulting at the National Hospital Rosales was conducted over a six-month period. Congenital heart disease patients were excluded. A survey, file review, and ELISA serological test were conducted for each subject. Results: Out of 455 subjects, 76 were seropositive for T. cruzi, giving a seropositivity prevalence of 16.7%. The average age of the patients was 58.09 years and the female:male ratio was 2.79:1. No significant difference was found between T. cruzi seropositive and seronegative patients in terms of age and gender. No association between T. cruzi serological status and either area of residence or seeing vectors in the house was found. However, living in the Salvadoran western region during childhood was significantly associated with seropositivity (p = 0.003). Other factors associated with T. cruzi seropositivity included: clinical diagnosis of cardiac Chagas disease; electrocardiographic (ECG) findings of a permanent pacemaker, all atrioventricular (AV) blocks and right bundle branch block; and grade III-IV radiological cardiomegaly. Conclusions: T. cruzi seropositivity prevalence was found to be 16.7% among heart disease patients in a public reference hospital.

show abstract

Section: Discussionmentioning

confidence: 48%

“…This fact should also call attention to the possibility of a higher T. cruzi infection rate in the Salvadoran population in the last decades than the rates published previously [3,8,9].…”

Section: Discussionmentioning

confidence: 84%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

ELISA seroprevalence of Trypanosoma cruzi in a cohort of heart disease patients

Rodriguez

Hernandez

Garcia

et al. 2013

J Infect Dev Ctries

View full text Add to dashboard Cite

show abstract

“…Además, como se mencionó anteriormente, la eficacia de la transmisión por transfusión de VIH y virus de la hepatitis B es superior a 75% en pacientes que han recibido sangre contaminada (12).…”

Section: Discussionunclassified

“…Los usuarios de drogas intravenosas, individuos con prácticas sexuales de riesgo y pacientes sometidos a múltiples transfusiones o hemodiálisis, constituyen las poblaciones con mayor riesgo de adquirir una infección por estos virus (8). La probabilidad de adquirir el virus por transfusión, aumenta con el número de unidades transfundidas, tiempo de exposición a las transfusiones, número de donantes de los cuales se recibe sangre o componentes y calidad de la tamización (12).…”

Section: Seroprevalence Of Hepatitis B Virus and Human Immunodeficienunclassified

Seroprevalencia de infección por virus de la hepatitis B y por virus de la inmunodeficiencia humana en una población de pacientes con múltiples transfusiones en cuatro hospitales, Colombia, Sur América

et al. 2009

View full text Add to dashboard Cite

Seroprevalencia de infección por virus de la hepatitis B y por virus de la inmunodeficiencia humana en una población de pacientes con múltiples transfusiones en cuatro hospitales, Colombia, Sur América Introducción. Aunque la transfusión de componentes sanguíneos es una terapia ampliamente utilizada, representa un riesgo de transmisión de agentes infecciosos. Objetivo. Como parte de la iniciativa sobre sangre segura promovida por la Organización Panamericana de la Salud, se realizó un estudio para estimar la seroprevalencia de infección por virus de la inmunodeficiencia humana y virus de la hepatitis B en pacientes con múltiples transfusiones en Colombia. Materiales y métodos. Entre febrero y septiembre de 2003, se llevó a cabo un estudio transversal de 500 pacientes con múltiples transfusiones, seleccionados en cuatro hospitales de las ciudades de Bogotá y Medellín. Las muestras de suero obtenidas se analizaron por inmunoensayo con estuches comerciales.Resultados. La frecuencia de seropositividad para el virus de la inmunodeficiencia humana fue de 1,8%, (IC95% 0,5-3,1). La frecuencia de seropositividad para el virus de la hepatitis B fue de 18,6% (IC95% 15,1-22,1). Los principales factores de riesgo fueron: recibir más de 48 unidades de sangre o componentes, tener diagnóstico de hemofilia, recibir transfusiones por un período mayor de un año, recibir sangre total, tener coinfección por virus de la hepatitis C y haber sido transfundido antes de 1993. Conclusiones. Este es el primer estudio epidemiológico realizado en Colombia con un número significativo de pacientes con múltiples transfusiones. El hallazgo más relevante es la elevada prevalencia de infección por virus de la hepatitis B y virus de la inmunodeficiencia humana observado en la población de hemofílicos, comparado con los otros cuatro grupos de pacientes con múltiples transfusiones. Palabras clave: transfusión sanguínea, VIH, virus de la hepatitis B, factores de riesgo, Colombia Seroprevalence of hepatitis B virus and human immunodeficiency virus infection in a population of multiply-transfused patients in ColombiaIntroduction. Although the transfusion of blood products is a common therapy, it carries risk of transmission of infections, especially hepatitus B virus (HBV) and human immunodeficiency virus (HIV).Objective. As part of the blood safety initiative, the Pan American Health Organization supported studies to estimate the prevalence of human immunodeficiency virus and hepatitis B virus infection in Colombia. Results. The seroprevalence of HIV infection was 1.8% (CI 95% 0.5-3.1). The seroprevalence of HBV infection was 18.6% (CI 95% 15.1-22.1). Six risk factors were associated with HIV and HBV infection: (1) receiving more than 48 units of blood or blood components, (2) diagnosis of hemophilia, (3) receiving transfusions for more than one year, (4) receiving whole blood, (5) coinfection with hepatitis C virus and (6) receiving transfusions before 1993.Conclusions. This is the first epidemiological study with a significant sample size performed i...

show abstract

Occult hepatitis C virus infection in Iranian patients with cryptogenic liver disease

Bokharaei‐Salim

Keyvani

Monavari

et al. 2011

Journal of Medical Virology

View full text Add to dashboard Cite

The diagnosis of cryptogenic liver disease is made when after extensive evaluations, recognizable etiologies of chronic liver disease are excluded. In this study, the presence of hepatitis C virus (HCV) RNA was tested in peripheral blood mononuclear cells (PBMCs) taken from Iranian patients who although were found negative for plasma HCV RNA and anti-HCV antibodies, suffered from chronic liver disease of unknown etiology. From September 2007 to March 2010, 69 patients from Tehran with chronic liver disease of unknown etiology who were referred to our center were enrolled in the present study. PBMCs were isolated from 10 mL peripheral blood specimens. HCV-RNA status was tested in plasma and PBMCs samples by reverse-transcription polymerase chain reaction (RT-PCR). HCV-RNA was detected in HCV-positive PBMCs specimens by RT-PCR method. HCV genotypes were subsequently analyzed in HCV-positive samples using restriction fragment length polymorphism (RFLP) assay; then HCV genotypes were confirmed by sequencing of 5' non-coding fragments after cloning PCR products into pJET1.2/blunt cloning vector. HCV-RNA was detected in PBMCs specimens belonging to 7 (10%) out of 69 patients. Genotyping of the HCV-RNA isolated from PBMCs showed that 3 (43%) patients with occult HCV infection had genotype 1b, 2 (29%) had genotype 1a, and another 2 (29%) had genotype 3a. The results of this study suggest that patients with chronic liver disease of unknown etiology may have occult HCV infection in the absence of anti-HCV antibodies and plasma HCV-RNA. It has been suggested that in the absence of liver biopsy specimens, analysis of PBMC sample for HCV-RNA would be informative.

show abstract

Risk for Transfusion-Transmitted Infectious Diseases in Central and South America

Cited by 84 publications

References 9 publications

ELISA seroprevalence of Trypanosoma cruzi in a cohort of heart disease patients

ELISA seroprevalence of Trypanosoma cruzi in a cohort of heart disease patients

Seroprevalencia de infección por virus de la hepatitis B y por virus de la inmunodeficiencia humana en una población de pacientes con múltiples transfusiones en cuatro hospitales, Colombia, Sur América

Occult hepatitis C virus infection in Iranian patients with cryptogenic liver disease

Contact Info

Product

Resources

About